Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome

Journal of the American Academy of Dermatology

Volumn 50, Issue 2, 2004, Pages 286-288

  Hebert, Adelaide A ^a,b   Bogle, Melissa A ^a  

^a University of Texas Health Science Center at Houston   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GAMMAR P; IMMUNOGLOBULIN; IOPAMIDOL; IOVERSOL; PREDNISONE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; FEMALE; HEART CATHETERIZATION; HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; STEVENS JOHNSON SYNDROME;

EID: 0842332452     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.07.017     Document Type: Article

References (7)

1. Revuz J. New advances in severe adverse drug reactions. Dermatol Clin 2001;19:697-709.
2. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282:490-93.
3. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351:1417-20.
4. Paul C, Wolkenstein P, Adle H, Wechsler J, Garchon HJ, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996;134:710-14.
5. Sung KJ, Paik EM, Jang KA, Suh HS, Choi JH. Apoptosis is induced by anti-Fas antibody alone in cultured human keratinocytes. J Dermatol 1997;24:427-34.
6. Lee SH, Jang JJ, Lee JY, Kim SY, Park WS, Shin MS, et al. Fas ligand is expressed in normal skin and in some cutaneous malignancies. Br J Dermatol 1998;139:186-91.
7. French LE, Tschopp J. Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition. Schweiz Med Wochenschr 2000;130:1656-61.